Galmed Announces First Time Results in Prostate Oncology Studies: Aramchol Demonstrates 3-4 Fold Increase in Cell Death Compared to Enzalutamide (XTANDI®) Alone in Prostate Cancer Models

Data ReadoutpositiveAramcholXtandiPositive

AI Analysis

Summary

Galmed announced preclinical results showing Aramchol demonstrating a 3-4 fold increase in cell death compared to enzalutamide alone in prostate cancer models. These are early-stage in vitro findings for the company's oncology program.

Clinical Trial Data

Outcome Details

Aramchol demonstrated 3-4 fold increase in cell death compared to enzalutamide alone in prostate cancer models

Importance:5/10

Sentiment:

0.70

oncologyprostate cancerpreclinicalcell deathcombination therapy

Related Companies

$GLMD

Read the original article

Published by PR Newswire Biotech on August 17, 2026 1:15 PM

Read Original